Browsing Closed Research Teams by author "De Bono, Johann"
Now showing items 1-20 of 25
-
A decade of clinical development of PARP inhibitors in perspective.
Mateo, J; Lord, CJ; Serra, V; Tutt, A; Balmaña, J; et al. (ELSEVIER, 2019-09-01)Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce ... -
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
Benson, C; White, J; De Bono, J; O'Donnell, A; Raynaud, F; et al. (NATURE PUBLISHING GROUP, 2007-01-15)Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour activity in a broad range ... -
A study of motivations and expectations of patients seen in phase 1 oncology clinics.
Dolly, SO; Kalaitzaki, E; Puglisi, M; Stimpson, S; Hanwell, J; et al. (WILEY-BLACKWELL, 2016-11-15)BACKGROUND: To better inform clinical practice, this study was aimed at capturing patients' motivations for enrolling in phase 1 trials and at quantifying their expectations of the benefits, risks, and commitment associated ... -
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard, G; Murphy, L; Clarke, NW; Cross, W; Jones, RJ; et al. (ELSEVIER SCIENCE INC, 2022-01-29)BACKGROUND: Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 ... -
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
James, ND; Clarke, NW; Cook, A; Ali, A; Hoyle, AP; et al. (WILEY, 2022-08-01)Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis ... -
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; et al. (MASSACHUSETTS MEDICAL SOC, 2017-07-27)BACKGROUND: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a ... -
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Hoyle, AP; Ali, A; James, ND; Cook, A; Parker, CC; et al. (ELSEVIER, 2019-12-01)BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the ... -
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; et al. (OXFORD UNIV PRESS, 2018-05-01)BACKGROUND: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ... -
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; et al. (ELSEVIER SCIENCE INC, 2016-03-19)BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ... -
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
Sundar, R; Custodio, A; Petruckevich, A; Chénard-Poirier, M; Ameratunga, M; et al. (ELSEVIER SCIENCE LONDON, 2018-03-01)AIMS: Advanced biliary tract carcinomas (ABC) are malignancies with limited effective therapies for advanced disease. There is little published evidence of outcomes of ABC patients participating in phase I clinical trials. ... -
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Geuna, E; Roda, D; Rafii, S; Jimenez, B; Capelan, M; et al. (NATURE PUBLISHING GROUP, 2015-12-01)BACKGROUND: PI3K-AKT-mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based toxicity of these agents and is becoming increasingly important with their use in larger numbers of ... -
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.
Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; et al. (CIG MEDIA GROUP, LP, 2017-10-01)BACKGROUND: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on ... -
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; et al. (AMER MEDICAL ASSOC, 2016-03-01)IMPORTANCE: The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ... -
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
Rafii, S; Roda, D; Geuna, E; Jimenez, B; Rihawi, K; et al. (AMER ASSOC CANCER RESEARCH, 2015-04-15)PURPOSE: Novel antitumor therapies against the PI3K-AKT-mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these agents are ... -
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.
Ang, JE; Pal, A; Asad, YJ; Henley, AT; Valenti, M; et al. (AMER ASSOC CANCER RESEARCH, 2017-10-01)MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular metabolism. Using quantitative mass spectrometry-based ... -
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
Moss, CA; Cojocaru, E; Hanwell, J; Ward, S; Xu, W; et al. (ELSEVIER SCI LTD, 2019-06-01)BACKGROUND: Molecular aberrations in cancer may represent therapeutic targets, and, if arising from the germline, may impact further cancer risk management in patients and their blood relatives. Annually, 600-700 patients ... -
Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.
Mehra, N; Sharp, A; Lorente, D; Dolling, D; Sumanasuriya, S; et al. (CIG MEDIA GROUP, LP, 2017-12-01)BACKGROUND: The neutrophil to lymphocyte ratio (NLR) has been shown to be highly prognostic across many tumor types, and predictive of treatment outcome in advanced prostate cancer, and has been postulated to be an indirect ... -
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
Ameratunga, M; Chénard-Poirier, M; Moreno Candilejo, I; Pedregal, M; Lui, A; et al. (ELSEVIER SCI LTD, 2018-01-01)BACKGROUND: Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought ... -
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Capelan, M; Roda, D; Geuna, E; Rihawi, K; Bodla, S; et al. (ELSEVIER IRELAND LTD, 2017-09-01)OBJECTIVES: Despite advances in novel drug development for patients with advanced non-small cell lung cancer (NSCLC), there are still only a limited number of approved treatments. We therefore evaluated the clinical outcomes ... -
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
Ang, JE; Pandher, R; Ang, JC; Asad, YJ; Henley, AT; et al. (AMER ASSOC CANCER RESEARCH, 2016-06-01)PI3K plays a key role in cellular metabolism and cancer. Using a mass spectrometry-based metabolomics platform, we discovered that plasma concentrations of 26 metabolites, including amino acids, acylcarnitines, and ...